Riesgo de las enfermedades tromboembólicas venosas de los fármacos oncológicos - page 7

Citostáticos clásicos
Cisplatino: fármaco con mayor riesgo
Incidencia ETE 18%
Mayor riesgo en los 3 primeros meses (>85%)
Dosis >30 mg/m2 semana
Se ha incluido en los scores de riesgo (PROTECHT score)
Metaanálisis: RR, 1.67; 95% CI, 1.25 to 2.23; p= 0.01
Tromboprofilaxis primaria?
Carboplatino
Riesgo intermedio (5,5% carbo vs 7% CDDP)
Moore et al. JCO 2011
Cancer ResTreat. 2015Jan2[Epubaheadof print]
pISSN1598-2998, eISSN2005-9256
http://dx.doi.org/10.4143/crt.2014.045
OpenAccess
Cisplatin-BasedChemotherapyIsa StrongRiskFactor for
ThromboembolicEventsinSmall-Cell LungCancer
Original Article
Purpose
Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an
increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using
cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However,
cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date.
The aim of this study was to determine the incidence of TEEs in patients with SCLC and to
analyze the predictors for TEE occurrence.
Yun-GyooLee, MD1,2,
EunyoungLee, MD1
InhoKim, MD,PhD1
Keun-WookLee, MD,PhD3
TaeMinKim, MD,PhD1
Se-HoonLee, MD,PhD1
Dong-WanKim, MD,PhD1